JAMA Dermatology: Multiple Sclerosis/Demyelinating Disease Topic Collection http://archderm.jamanetwork.com/ en-us Wed, 26 Dec 2012 00:00:00 GMT Tue, 01 Jan 2013 00:49:08 GMT Silverchair editor@archderm.jamanetwork.com webmaster@archderm.jamanetwork.com Melanoma Occurring During Treatment With Fingolimod for Multiple Sclerosis: A Case Report http://archderm.jamanetwork.com/article.aspx?articleID=1105268 Mon, 01 Aug 2011 00:00:00 GMT Conzett K, Kolm I, Jelcic I, et al. <span class="paragraphSection">The immunosuppressant drug FTY720 inhibits lymphocyte emigration from lymphoid organs. The phase III TRANSFORMS trial showed no melanomas in 420 patients treated with 1.25-mg/d FTY720, 3 melanomas in 429 patients treated with 0.5-mg/d FTY720, and no melanomas in 431 patients treated with interferon beta-1a. In the FREEDOMS trial over 24 months, 1 melanoma occurred in 429 patients treated with 1.25-mg/d FTY720, no melanomas in 425 patients treated with0.5-mg/d FTY720, and 1 melanoma in 418 patients taking placebo. A 3-year phase II study showed 1 melanoma in the placebo/FTY720 group after 25 months and 1 melanoma in the 1.25-mg/d FTY720 group after 36 months.</span> 147 8 991 992 10.1001/archdermatol.2011.212 http://archderm.jamanetwork.com/article.aspx?articleID=1105268